Stocks · News reference
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects Of ATYR0101 In Journal Of Biological Chemistry
Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis.ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
aTyr Pharma reached FDA alignment on a Phase 3 study for efzofitimod to treat pulmonary sarcoidosis, beginning in Q4 2026.
8-K filing — aTYR PHARMA INC (ATYR)
Filed: 2026-09-24 AccNo: 0001339970-26-000065 Size: 172 KB Item 8.01: Other Events